On January 13, 2017, LifeTech Scientific Corporation, the leading supplier of minimally invasive interventional cardiovascular  devices and an innovation-driven leader in the industry, was recognized by the capital market and was awarded the honor of  "Public Company with the Biggest Growth Potential" of 2016.

The high-level award event was co-organized by Zhitongcaijing.com and Hithink Flush Information Network Co., Ltd. and supported by the Hong Kong Stock Exchange and the Shenzhen Stock Exchange, presented 11 awards including "Public Company with the Biggest Growth Potential" to Hong Kong listed companies with an outstanding performance in 2016. The awards were based on the review and evaluation of company operating data by an expert panel and the voting by public investors.

The Executive Director and CFO of LifeTech, Mr. LIU Jianxiong attended the award ceremony and accepted the award on behalf of the company on January 13. The winning of this prestigious award has fully shown the recognition in the capital market of LifeTech's outstanding performance in extensive indicators, including the growth of market cap, return to shareholders, value creation capacity, corporate governance, sustainable development, as well as business growth potential. Since LifeTech Scientific Corporation went to public in Hong Kong in November 2011, the share price has increased by nearly eight times in five years, delivering a compound annual growth rate of net profit was as high as to 37.8%. In addition, the company has become among the few Chinese enterprises in minimally invasive interventional cardiovascular devices field that has established a strong global presence through independent innovation.

Image: Executive Director and CFO of LifeTech, Mr. LIU Jianxiong (the second on the left) accepts the award on behalf of the company 

Under the background of the launch of the Shenzhen-Hong Kong Stock Connect, LifeTech Scientific Corporation will continue to focus on its core business in furtherance of its commitment to providing doctors and patients around the world with innovative, technologically advanced high-quality medical devices while delivering compelling value and attractive return to investors.